Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial

Fang, Wenfeng1; Zhao, Yuanyuan1; Luo, Yongzhong2; Yang, Runxiang3; Huang, Yan1; He, Zhiyong4; Zhao, Hui5; Li, Mingjun6; Li, Kai7; Song, Qibing8; Du, Xiaobo9; Sun, Yulan10; Li, Wei11; Xu, Fei12; Wang, Zhiyu13; Yang, Kunning14; Fan, Yun15; Liu, Baogang16; Zhao, Hongyun1; Hu, Ying17; Jia, Li18; Xu, Shen19; Yi, Tienan20; Lv, Dongqing21; Lan, Haitao22; Li, Mengxia23; Liang, Wenhua24; Wang, Yongsheng25; Yang, Hui26; Jia, Yuming27; Chen, Yuan28; Lu, Junguo29; Feng, Jifeng30; Liu, Chunling31; Zhou, Ming32; Zhou, Jianya33; Liu, Xianling34; Zhou, Ningning1; He, Ming13; Dong, Xiaorong35; Chen, Hualin36; Chen, Yongxing37; Su, Haichuan38; Li, Xiaoling39; Zhang, Zhihong40; Yang, Lei41; Cheng, Ying42; Chen, Likun1; Hou, Xue1; Zhang, Yu43; Guo, Jun44; Wang, Zhen45; Lu, Hong46; Wu, Di47; Feng, Weineng48; Li, Wen49; Huang, Jianan50; Wang, Yan51; Song, Xia52; Peng, Jiewen53; Liu, Laiyu54; Guo, Yubiao55; Li, Wenting56; Lu, Dongmei56; Hu, Mingxiu56; Wang, Zhongmin Maxwell56; Li, Baiyong56; Xia, Michelle56; Zhang, Li1

2024-08-01

10.1001/jama.2024.10613

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION   影响因子和分区

0098-7484

1538-3598

Importance For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. Objective To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant. Design, Setting, and Participants Double-blind, placebo-controlled, randomized, phase 3 trial at 55 sites in China enrolled participants from January 2022 to November 2022; a total of 322 eligible patients were enrolled. Interventions Participants received ivonescimab (n = 161) or placebo (n = 161) plus pemetrexed and carboplatin once every 3 weeks for 4 cycles, followed by maintenance therapy of ivonescimab plus pemetrexed or placebo plus pemetrexed. Main Outcomes and MeasuresThe primary end point was progression-free survival in the intention-to-treat population assessed by an independent radiographic review committee (IRRC) per Response Evaluation Criteria in Solid Tumors version 1.1. The results of the first planned interim analysis are reported. Results Among 322 enrolled patients in the ivonescimab and placebo groups, the median age was 59.6 vs 59.4 years and 52.2% vs 50.9% of patients were female. As of March 10, 2023, median follow-up time was 7.89 months. Median progression-free survival was 7.1 (95% CI, 5.9-8.7) months in the ivonescimab group vs 4.8 (95% CI, 4.2-5.6) months for placebo (difference, 2.3 months; hazard ratio [HR], 0.46 [95% CI, 0.34-0.62]; P < .001). The prespecified subgroup analysis showed progression-free survival benefit favoring patients receiving ivonescimab over placebo across almost all subgroups, including patients whose disease progressed while receiving third-generation EGFR-TKI therapy (HR, 0.48 [95% CI 0.35-0.66]) and those with brain metastases (HR, 0.40 [95% CI, 0.22-0.73]). The objective response rate was 50.6% (95% CI, 42.6%-58.6%) with ivonescimab and 35.4% (95% CI, 28.0%-43.3%) with placebo (difference, 15.6% [95% CI, 5.3%-26.0%]; P = .006). The median overall survival data were not mature; at data cutoff, 69 patients (21.4%) had died. Grade 3 or higher treatment-emergent adverse events occurred in 99 patients (61.5%) in the ivonescimab group vs 79 patients (49.1%) in the placebo group, the most common of which were chemotherapy-related. Grade 3 or higher immune-related adverse events occurred in 10 patients (6.2%) in the ivonescimab group vs 4 (2.5%) in the placebo group. Grade 3 or higher vascular endothelial growth factor-related adverse events occurred in 5 patients (3.1%) in the ivonescimab group vs 4 (2.5%) in the placebo group. Conclusions Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in TKI-treated non-small cell lung cancer.

SCI

英语

其他

Chinese National Natural Science Foundation["82241232","82272789","82373262","82173101"]

General & Internal Medicine

Medicine, General & Internal

WOS:001236370600001

AMER MEDICAL ASSOC

CLINICAL MEDICINE

Web of Science

1.Sun Yat Sen Univ, Canc Ctr, 651 Dong Feng Rd E, Guangzhou 510060, Guangdong, Peoples R China
2.Hunan Canc Hosp, Changsha, Peoples R China
3.Yunnan Canc Hosp, Kunming, Peoples R China
4.Fujian Prov Tumor Hosp, Fuzhou, Peoples R China
5.Anhui Med Univ, Hosp 2, Hefei, Peoples R China
6.Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
7.Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
8.Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China
9.Mianyang Cent Hosp, Mianyang, Peoples R China
10.Shandong Canc Prevent & Treatment Inst, Jinan, Peoples R China
11.Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China
12.Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China
13.Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
14.Weifang 2 Peoples Hosp, Weifang, Peoples R China
15.Zhejiang Canc Hosp, Hangzhou, Peoples R China
16.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
17.Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China
18.Yuncheng Cent Hosp Shanxi Prov, Yuncheng, Peoples R China
19.Zhangzhou Municipal Hosp Fujian Prov, Zhangzhou, Peoples R China
20.Xiangyang Cent Hosp, Xiangyang, Peoples R China
21.Taizhou Municipal Hosp, Taizhou, Peoples R China
22.Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
23.Army Med Ctr Chinese Peoples Liberat Army, Chongqing, Peoples R China
24.Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
25.Sichuan Univ, West China Hosp, Chengdu, Peoples R China
26.Xiamen Med Coll, Affiliated Hosp 2, Xiamen, Peoples R China
27.Yibin Second Peoples Hosp, Yibin, Peoples R China
28.Tongji Hosp, Tongji Med Coll Hust, Wuhan, Peoples R China
29.Nantong Tumor Hosp, Nantong, Peoples R China
30.Jiangsu Canc Hosp, Nanjing, Peoples R China
31.Xinjiang Med Univ, Affiliated Tumor Hosp, Urumqi, Peoples R China
32.Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China
33.Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
34.Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China
35.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
36.Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
37.Hainan Gen Hosp, Haikou, Peoples R China
38.Fourth Mil Med Univ, Tangdu Hosp, Xian, Peoples R China
39.Dalian Univ Technol, Liaoning Canc Hosp & Inst, Canc Hosp, Shenyang, Peoples R China
40.Anhui Prov Canc Hosp, Hefei, Peoples R China
41.Gansu Prov Canc Hosp, Lanzhou, Peoples R China
42.Jilin Canc Hosp, Changchun, Peoples R China
43.Nanjing Chest Hosp, Nanjing, Peoples R China
44.Xingtai Peoples Hosp, Xingtai, Peoples R China
45.Linyi Canc Hosp, Linyi, Peoples R China
46.Henan Univ, Huaihe Hosp, Kaifeng, Peoples R China
47.Southern Univ Sci & Technol, Clin Med Coll 2, Shenzhen Peoples Hosp, Jinan Univ,Shenzhen Inst Resp Dis,Shenzhen Peoples, Shenzhen, Peoples R China
48.First Peoples Hosp Foshan, Foshan, Peoples R China
49.Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
50.Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
51.Ningxia Med Univ, Gen Hosp, Yinchuan, Peoples R China
52.Shanxi Canc Hosp, Taiyuan, Peoples R China
53.Zhongshan City Peoples Hosp, Zhongshan, Peoples R China
54.Nanfang Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
55.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
56.Akeso Biopharm Inc, Zhongshan, Peoples R China

Fang, Wenfeng,Zhao, Yuanyuan,Luo, Yongzhong,et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,2024.

Fang, Wenfeng.,Zhao, Yuanyuan.,Luo, Yongzhong.,Yang, Runxiang.,Huang, Yan.,...&Zhang, Li.(2024).Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial.JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION.

Fang, Wenfeng,et al."Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial".JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2024).